ReviewReviews in endocrine & metabolic disorders2009
Somatostatin-dopamine ligands in the treatment of pituitary adenomas.
Review in Reviews in endocrine & metabolic disorders, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 39 citations in OpenAlex.
- Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary Adenomas.Molecular neurobiology · 2017Article
- Review
- Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.Molecular endocrinology (Baltimore, Md.) · 2016Article
- A survey of clinical practice patterns in diagnosis and management of Cushing's disease in Iran.Medical journal of the Islamic Republic of Iran · 2016Article
- Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement.Frontiers in endocrinology · 2015Review
- Molecular basis of pharmacological therapy in Cushing's disease.Endocrine · 2014Review
- PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors.TheScientificWorldJournal · 2014Article
- Peptide receptor targeting in cancer: the somatostatin paradigm.International journal of peptides · 2013Article
- Article
- Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications.Journal of cellular and molecular medicine · 2010Review
- Nonfunctioning pituitary adenomas: the Oxford experience.Nature reviews. Endocrinology · 2009Review
- Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly.The Journal of clinical endocrinology and metabolism · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Somatostatin receptors (sst1-5) and dopamine receptor 2 (D2DR) are well expressed and co-localized in several human pituitary adenomas, suggesting possible functional interactions in the control of hormonal hypersecretion and tumor cell growth. The present review describes the expression and functionality of these receptors in the different classes of human pituitary adenomas. The sst2 agonists, octreotide and lanreotide, control GH hypersecretion and tumor growth in about 65% of somatotropinomas. The D2DR agonists, bromocriptine and cabergoline, control about 90% of prolactinomas. Such drugs are much less effective in the control of the others pituitary adenomas also expressing ssts and D2DR receptors. The second part summarizes the current knowledge on new chimeric compounds with sst2, sst5, and D2DR affinity. Such ligands bearing distinct ssts and DRD2 pharmacophores may synergistically produce an increased control of secretion and/or of proliferation in the different types of pituitary adenomas. The mechanisms of action of such chimeric molecules through increased binding affinities, prolonged bioavailability, ligand-induced modulation of receptors heterodimerization, are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.